


Amodel







Gene function


Nelson et al Nature Genetics 2015



Gene function








An example in immunology

Example of allelic series model: TYK2

- TYK2 is an intracellular signaling molecule (next slide)
- Rare, complete human knockout is associated with immunodeficiency and risk of infection
- Common protein coding alleles reduce TYK2 function and protect from risk of autoimmune disease (e.g., psoriasis, RA, SLE, IBD)
- Same common alleles do not increase risk of infection

IL23 signaling and psoriasis



TYK2 gene

Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis


and type 1 diabetes

000 400 Harm-Jan Westra^{1,2,3,4,5,20}, Marta Martínez-Bon 400 Yang Luo^{1,2,3,4}, Nikola Teslovich^{1,2,3,4}, Jane Worth 000 Dataset Frequency Odds Ratio 0 - N Lars Klareskog¹³, Solbritt Rantapaa-Dahlqvist¹⁴ 702 John A. Todd¹⁷, Steve Eyre^{9,10}, Peter A. Nigrovic⁴ Cases Controls 0.5 450 Soumya Raychaudhuri (1)1,2,3,4,9,19* 300 GIGIA Combined 0.897 0.88 (reference) (reference) 0.898 0.874 T1D (reference) RA 0.896 0.877 CIGIA Combined 0.022 0.032 P1104A 0.022 0.033 T1D RA 0.023 0.034 GIGIC Combined 0.081 0.088 **1684S** T1D 0.08 0.093 0.081 RA 0.089 (low freq: A928V)

AUTOIMMUNITY

Resolving *TYK2* locus genotype-to-phenotype differences in autoimmunity

Calliope A. Dendrou,¹ Adrian Cortes,^{1,2} Lydia Shipman,¹ Hayley G. Evans,¹ Kathrine E. Attfield,³ Luke Jostins,² Thomas Barber,¹ Gurman Kaur,³ Subita Balaram Kuttikkatte,³ Oliver A. Leach,¹ Christiane Desel,¹ Soren L. Faergeman,^{1,4} Jane Cheeseman,⁵ Matt J. Neville,^{5,6} Stephen Sawcer,⁷ Alastair Compston,⁷ Adam R. Johnson,⁸ Christine Everett,⁸ John I. Bell,⁹ Fredrik Karpe,^{5,6} Mark Ultsch,⁸ Charles Eigenbrot,⁸ Gil McVean,² Lars Fugger^{1,3,4}*



P1104A allele that protects from autoimmunity is associated with ~80% loss-of-function (LoF) in C/C homozygous state

Same LoF allele has no obvious increased risk of infection


		Rs34536443 genotype				
		G/G	G/C	C/C	Total	
normal	In U.K. Biobank	105,794 (90.63%)	10,689 (9.16%)	249 (0.21%)	116,732 (100%)	
Infections	Mycobacterial	20 (86.96%)	3 (13.04%)	0 (0.00%)	23	
	Specific bacterial (For example, <i>S. aureus</i>)	54 (90.00%)	5 (8.33%)	1 (1.67%)	60	
	Specific viral (e.g. HSV, VZV, viral encephalitis)	93 (96.88%)	3 (3.12%)	0 (0.00%)	96	
	Mucocutaneous candidiasis	46 (88.46%)	6 (11.54%)	0 (0.00%)	52	
	Total	213 (92.21%)	17 (7.36%)	1 (0.43%)	231	

~80% LoF is not associated with increased infection


Dendrou, et al. (2016) Science Translational Medicine


P1104A protects from multiple autoimmune diseases







But 1684S variant shows a more complicated pattern!








Risk of autoimmune disease




Risk of autoimmune disease

But matching *modality with mechanism* is challenging, especially selectivity over JAKs




Risk of autoimmune disease




Risk of autoimmune disease


Matching modality and mechanism: "pseudokinase stabilizers" recapitulate human genetic mutations at functional level



50-80% TYK2 inhibition safe and effective in Phase 2 (psoriasis)




Matching modality with mechanism is a ratelimiting event in drug R&D



While we often first think of "conventional" small molecule and monoclonal antibodies...

...there are many burgeoning therapeutic modalities




Go to examples



Other

mRNA replacement protein degradation macrocyclic peptides microbiome

...and more to come!



What does the future hold?

What would be transformational?

Five key areas to realize this future state

- Genetic dose-response portal beyond GWAS
 - Continued genetic discovery with function / phenotype integrations
- Causal human biology beyond germline genetics
 - Human pharmacology and human immunology
- Matching modality & mechanism beyond "conventional" medicines
 - Cell and gene therapy for "living" therapeutics
- Programmable therapeutics beyond linear drug R&D
 - Approved platform for all but final registrational trials
- Digital confluence beyond wearables and Al
 - When discovery, development, and the real-world collide

How to build a genetic dose-response portal

Genetic architecture of human disease

- continued sequencing of rare, Mendelian diseases
- human knockout project (e.g., dbLoF)
- exome sequencing in case-control cohorts

Functional interrogation

- high-throughput assessment of mutations
- single cell analyses in disease tissues at population scale


Pleiotropy

- integrated population-based biobanks with genotype / phenotype data
- quantitative traits as biomarkers

Data analysis

- statistical methods to model dose-response
- data integration and visualization

Blog on plengegen.com



Go to PheWAS



Go to IL6R



Go to pQTL and MR

Causal human biology – beyond genetics

Human pharmacology

- Effective pharmacology (e.g., low-dose IL2 in autoimmunity)
- Rationale combinations (e.g., apremilast + other MoA)
- Non-responder populations (e.g., resistance to checkpoint inhibitors)
- Bi-specifics (e.g., tissue targeting, T cell engagers)

Go to apremilast



Human immunology

- Mapping peptide epitopes for autoantigens in autoimmunity
- TCR and BCR sequencing of pathogenic lymphocytes in autoimmunity
- Single-cell profiling is disease tissue (e.g., NIH-funded AMP)
- Cloning therapeutic antibodies from elite responders
- Cloning TCRs and BCRs for cell therapy
- Characterization of neoantigens for cancer immune therapy

Go to vasculitis, celiac



Go to neoantigens



Blog on plengegen.com

New therapeutic modalities – beyond conventional molecules

- Nucleic acid-based therapies
 - Cell therapies (e.g., CAR-T)
 - ex vivo gene replacement (e.g., PID)
 - mRNA gene replacement
 - Genome editing (e.g., CRISPR)
 - Anti-sense oligonucleotides (ASOs)
 - Small interfering RNA (siRNA)
- Non-nucleic acid-based therapies
 - Protein degradation
 - Microbiome
 - Peptides (e.g., tolerizing antigens)

Go to cell therapy



Go to modalities




Blog on plengegen.com


Programmable therapeutics for gene replacement

Conventional approach: one gene, one disease, one linear regulatory path to approval (e.g., pre-clinical biology, toxicology, CMC, early clinical dev, registrational trials)

<u>Programmable approach</u>: introduce a new gene into a "programmable" platform that has been approved for all pre-registrational trial activities



Digital confluence




might 0 2017 by The Sastan Consult ing Group, Inc., All rights reserved.


Back-ups

Mendelian randomization


Mendelian randomization: nature's clinical trial




Mendelian randomization: nature's clinical trial



Genetics can bridge biomarker with clinical data, establishing a causal link for drug discovery




Large-scale proteomic databases are limiting




Emerging resource of pQTLs for MR

- Tested 3,622 plasma proteins in 3,301 healthy individuals from INTERVAL population cohort
- Identified 1,927 genetic associations with 1,478 proteins
- Example: *IL-6R* RA protective allele increases sIL-6R levels (see figure) but decreases membrane-bound IL6R
- Therapeutic hypothesis: preventing IL-6 signaling through IL-6R via blocking antibodies should treat RA symptoms

Sun, Maranville et al (2018) Nature



Mendelian randomization establishes a causal link between IL-6 pathway and risk of rheumatoid arthritis



IL-6R minor variant




Less membrane IL-6R and less signaling



Protection from RA


Thus, therapeutic targeting of IL-6R should be beneficial in treating RA patients

Tocilizumab mimics mutation by reducing IL-6R signaling



Phenome-wide association study (PheWAS)

Phenome-wide association studies (PheWAS)



https://doi.org/10.1038/s41588-018-0216-7

Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis

and type 1 diabetes

Harm-Jan Westra^{1,2,3,4,5,20}, Marta Martínez-Bonet ^{6,20}, Suna Yang Luo^{1,2,3,4}, Nikola Teslovich^{1,2,3,4}, Jane Worthington^{9,10}, Jav Lars Klareskog¹³, Solbritt Rantapaa-Dahlqvist¹⁴, Wei-Min Che John A. Todd¹⁷, Steve Eyre^{9,10}, Peter A. Nigrovic^{4,18}, Peter K. Gre Soumya Raychaudhuri 101,2,3,4,9,19*

rs35667974 protects from T1D

rs72871627 protects from T1D

ATA haplotype – protects from T1D




IFIH1 gene

1485 67974 71627	Dataset	Frequency		Odds-ratio	
rs211 rs356 rs728		Cases	Controls	0.4	1
GITIA	Combined	0.621	0.599	(reference	ce)
	T1D	0.638	0.596	(reference	ce)
AICIA	Combined	0.016	0.02	-0-	- 1
	T1D	0.01	0.021	-0-	i i
GITIG	Combined	0.009	0.011	-	—:
	T1D	0.008	0.014	-	ì
AITIA	Combined	0.354	0.371		
	T1D	0.344	0.37	4	- !


PheWAS example: IFIH1, autoimmunity, asthma

- PheWAS in ~800,000 individuals from four population cohorts
- Tested 25 SNPs for association with 1,683 clinical endpoints
- 10 novel associations discovered
- Example: *IFIH1* LOF allele protects from autoimmunity (known) but increases risk of asthma (novel finding)
- Therapeutic hypothesis: inhibiting IFIH1 may be effective in some autoimmune diseases but may make asthma worse




Diogo et al (2018) Nature Communications

Predicted impact of therapeutic inhibition of IFIH1




FinnGen is a unique PheWAS resource



IL6R as a validated target


Two forms of IL-6R: soluble and membrane-bound



- Cis-signaling via membrane bound IL-6 receptor complex
- Trans-signaling via soluble IL-6 receptor
- Levels are inversely related: more sIL-6R, less mIL-6R
- What is the effect of the protective allele on IL-6R?

Initial observations confusing: protective RA allele appeared was associated with more circulating IL-6R


More *soluble* IL-6R, but...




A (Asp) = risk allele C (Ala) = protective allele

Ferreira et al. (2013) PLoS Genetics

Protective *IL-6R* variant consistent w/ loss-of-function






A (Asp) = risk allele C (Ala) = protective allele

Ferreira et al. (2013) PLoS Genetics

Protective IL-6R variant consistent w/ loss-of-function


Less cell surface IL-6R leads to less IL-6R signaling across cell types




A (Asp) = risk allele C (Ala) = protective allele

Ferreira et al. (2013) PLoS Genetics

PheWAS-like approach predicts benefit of anti-IL6R therapy (tocilizumab) in coronary heart disease



PheWAS-like approach can differentiate between ontarget vs off-target effects of a drug



Drug but not protective allele has effect on cholesterol levels


Off-target ADE

Protective allele and drug leads to more sIL-6 but less CRP and fibrinogen

On-target effect

(standardised mean difference per minor allele rs7529229)

PheWAS via electronic health records (EHR) can identify indications for drug repurposing



Pre-clinical proof-of-concept in pemphigus vulgaris


IMMUNOTHERAPY

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease


Christoph T. Ellebrecht, Vijay G. Bhoj, Arben Nace, Eun Jung Choi, Xuming Mao, Michael Jeffrey Cho, Giovanni Di Zenzo, Antonio Lanzavecchia, John T. Seykora, George Cotsarelis, Michael C. Milone, Almee S. Payne**

Ideally, therapy for autoimmune diseases should eliminate pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an approach have been elusive. Here, we show that in the antibody-mediated autoimmune disease pemphigus vulgaris (PV), autoantigen-based chimeric immunoreceptors can direct T cells to kill autoreactive B lymphocytes through the specificity of the B cell receptor (BCR). We engineered human T cells to express a chimeric autoantibody receptor (CAAR), consisting of the PV autoantigen, desmoglein (Dsg) 3, fused to CD137-CD3 ζ signaling domains. Dsg3 CAAR-T cells exhibit specific cytotoxicity against cells expressing anti-Dsg3 BCRs in vitro and expand, persist, and specifically eliminate Dsg3-specific B cells in vivo. CAAR-T cells may provide an effective and universal strategy for specific targeting of autoreactive B cells in antibody-mediated autoimmune disease.

Dsg3 CAAR




control CAR





Gene and mRNA therapy as programmable therapeutics


Gene therapy landscape – three approvals, more to come



Primary immunodeficiency (PID) – hundreds of genes implicated, but fewer than 5 in development

- Over 350 genes implicated in PID
- Range of phenotypes
 - Severe Combined Immune Deficiency (SCID): profound hypersusceptibility to infections and/or cancer
 - Moderate: increased risk of infection, chronic dermatologic conditions, persistent autoimmunity, inflammatory bowel disease, chronic lung conditions (e.g., fibrosis, asthma)
- Total incidence approaches 1% of the population
 - SCID estimated at 1 / 30,000 live births (or ~150 new cases in US each year)
- TREC assay for SCID now part of newborn screening in 50 US states (as of 2018)
- Foundations (e.g., <u>JMF</u>) actively involved in patient advocacy, research, more
 - 792 physicians at 358 institutions in 277 cities across 86 countries spanning 6 continents
- Approximately two-thirds of severe PID is amenable to cures via HSCT
- Gene therapy successful, but only 1 gene (out of 350) with a marketed product
- How will durable cures be achieved for the entire patient population?


Autologous ex vivo gene replacement for PID leads to cure



Programmable therapeutics for PID

<u>Conventional approach</u>: one gene, one disease, one linear regulatory path to approval (e.g., pre-clinical biology, toxicology, CMC, early clinical dev, registrational trials)

ADA WAS GCD Pre-clinical biology toxicology CMC Early clinical dev. Registrational trial Regulatory approval <u>Programmable approach</u>: introduce a new gene into a "programmable" platform that has been approved for all pre-registrational trial activities




Regulatory approval

mRNA therapy as programmable therapeutic in oncology

Many mechanisms of resistance to checkpoint inhibitors

Table 2. Mechanisms of Primary and Adaptive Resistance to Immunotherapy

	Mechanism	Examples
tumor cell intrinsic	absence of antigenic proteins	low mutational burden lack of viral antigens lack of cancer-testis antigens overlapping surface proteins
	absence of antigen presentation	deletion in TAP deletion in B2M silenced HLA
	genetic T cell exclusion	MAPK oncogenic signaling stabilized b-catenin mesenchymal transcriptome oncogenic PD-L1 expression
	insensibility to T cells	mutations in interferon gamma pathway signaling
tumor cell extrinsic	absence of T cells	lack of T cells with tumor antigen-specific TCRs
	inhibitory immune checkpoints	VISTA, LAG-3, TIM-3
	immunosuppressive cells	TAMs, Tregs



Sharma et al Cell (2017)

High diversity of neoantigens requires programmable approach


LETTER

doi:10.1038/nature22991


An immunogenic personal neoantigen vaccine for patients with melanoma

Patrick A. Ott^{1,2,3*}, Zhuting Hu^{1*}, Derin B. Keskin^{1,3,4}, Sachet A. Shukla^{1,4}, Jing Sun¹, David J. Bozym¹, Wandi Zhang¹, Adrienne Luoma⁵, Anita Giobbie–Hurder⁶, Lauren Peter^{7,8}, Christina Chen¹, Oriol Olive¹, Todd A. Carter⁴, Shuqiang Li⁴, David J. Lieb⁴, Thomas Eisenhaure⁴, Evisa Gjini⁹, Jonathan Stevens¹⁰, William J. Lane¹⁰, Indu Javeri¹¹, Kaliappanadar Nellaiappan¹¹, Andres M. Salazar¹², Heather Daley¹, Michael Seaman⁷, Elizabeth I. Buchbinder^{1,2,3}, Charles H. Yoon^{3,13}, Maegan Harden⁴, Niall Lennon⁴, Stacey Gabriel⁴, Scott J. Rodig^{9,10}, Dan H. Barouch^{3,7,8}, Jon C. Aster^{3,10}, Gad Getz^{3,4,14}, Kai Wucherpfennig^{3,5}, Donna Neuberg⁶, Jerome Ritz^{1,2,3}, Eric S. Lander^{3,4}, Edward F. Fritsch^{1,4}†, Nir Hacohen^{3,4,15} & Catherine J. Wu^{1,2,3,4}

To generate a vaccine that targets personal neoantigens, we conducted whole-exome sequencing (WES) of matched tumour- and normal-cell DNA from individual patients, identified somatic mutations, orthogonally validated and assessed the expression of mutated alleles by RNA sequencing (RNA-seq) of the tumour, predicted which mutated peptides were likely to bind autologous HLA-A or HLA-B proteins of the patient, and synthesized clinical-grade long peptides³ targeting up to 20 neoantigens per patient, admixed with the Toll-like receptor 3 (TLR3) and melanoma differentiation-associated protein 5 (MDA-5)



mRNA replacement as programmable therapeutic in oncology



Durable anticancer immunity from intratumoral administration of IL-23, IL-36 γ , and OX40L mRNAs

Susannah L. Hewitt*, Ailin Bai*, Dyane Bailey, Kana Ichikawa, John Zielinski, Russell Karp, Ameya Apte, Kristen Arnold, Sima J. Zacharek, Maria S. Iliou, Khushbu Bhatt, Maija Garnaas, Faith Musenge, Ashley Davis, Nikhil Khatwani, Stephen V. Su, Graham MacLean, Samuel J. Farlow, Kristine Burke, Joshua P. Frederick[†]

